2010
DOI: 10.1016/j.addr.2009.11.009
|View full text |Cite
|
Sign up to set email alerts
|

Chitosan-based delivery systems for protein therapeutics and antigens

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

8
289
0
6

Year Published

2010
2010
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 557 publications
(304 citation statements)
references
References 198 publications
8
289
0
6
Order By: Relevance
“…TMC nanoand micro-particles have been fabricated by ionic cross-linking with different polyanions, such as polyglutamic acid, TPP, sodium sulfate, dextran sulfate, and anionic cyclodextrins. 18 The acidic environment of the stomach and enzymes pose significant challenges to the oral administration of vaccines. Figure 2.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…TMC nanoand micro-particles have been fabricated by ionic cross-linking with different polyanions, such as polyglutamic acid, TPP, sodium sulfate, dextran sulfate, and anionic cyclodextrins. 18 The acidic environment of the stomach and enzymes pose significant challenges to the oral administration of vaccines. Figure 2.…”
Section: Discussionmentioning
confidence: 99%
“…However, limited solubility has prevented its widespread use. 9,10 The mucoadhesive and absorption-promoting properties of chitosan have been extensively evaluated. The positive charge gained in acidic pH conditions, in which chitosan has high solubility, appears to be effective for enhanced absorption.…”
Section: Introductionmentioning
confidence: 99%
“…The primary amine groups introduce special properties that render chitosan very useful for pharmaceutical applications. Because of the presence of functional groups (amine and hydroxyl) various chemical chitosan derivatives have been synthesized and studied for different applications [3,4].…”
Section: Introductionmentioning
confidence: 99%
“…Lysostaphin, a zinc metalloenzyme in S. simulans (Schindler & Schuhardt, 1964), is lytic against S.aureus cells, and has shown high potentials in the treatment of antibiotic-resistant S.aureus (Bhakta et al, 2003) and methicillin-resistant S.aureus (MRSA) infections (Dajcs et al, 2000). However, Amidi et al (2010) reviewed that the short residence time of the current formulations in the nasal cavity due to mucociliary clearance posed a severe limitation for the drug delivery in the nasal cavity. Kokai-Kun et al (2003) and Walsh et al (2004) prepared a semi-solid cream and found that the cream greatly enhanced the efficacy of lysostaphin against S.aureus nasal colonization in cotton rats.…”
Section: Introductionmentioning
confidence: 99%